Botanix Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Botanix Pharmaceuticals's earnings have been declining at an average annual rate of -57.1%, while the Pharmaceuticals industry saw earnings growing at 5.8% annually. Revenues have been growing at an average rate of 20.6% per year.
Key information
-57.10%
Earnings growth rate
-41.44%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.22% |
| Revenue growth rate | 20.56% |
| Return on equity | -164.28% |
| Net Margin | -404.72% |
| Last Earnings Update | 31 Dec 2025 |
Recent past performance updates
Recent updates
BOT: Commercial Launch Execution Will Drive Future Upside Potential
Analysts have reset their price expectations for Botanix Pharmaceuticals, cutting the fair value estimate from A$0.21 to A$0.14. They cite updated assumptions for discount rate, revenue growth, profit margins, and a lower future P/E multiple.
BOT: Future Share Dilution From Large Capital Raising Will Drive Upside Potential
Analysts have reset their fair value estimate for Botanix Pharmaceuticals from A$0.83 to A$0.49, reflecting updated assumptions for the discount rate, revenue growth, profit margins, and a much lower future P/E multiple. What's in the News Botanix Pharmaceuticals completed a follow on equity offering of A$4.999999 million in ordinary shares, comprising 14,341,646 securities at A$0.06 each with attached options, plus an additional 68,991,667 ordinary shares at A$0.06 each with attached options.
Bullish View That A Scalable Dermatology Platform Will Transform An Underserved Hyperhidrosis Market
Catalysts About Botanix Pharmaceuticals Botanix Pharmaceuticals is a dermatology company focused on commercialising Sofdra for primary axillary hyperhidrosis and leveraging its U.S. commercial platform. What are the underlying business or industry changes driving this perspective?Single Product And API Constraints Will Shape Dermatology Platform Potential Over The Long Term
Catalysts About Botanix Pharmaceuticals Botanix Pharmaceuticals is a dermatology company focused on Sofdra, a prescription treatment for primary axillary hyperhidrosis supported by its own fulfillment platform. What are the underlying business or industry changes driving this perspective?Long-Term Hyperhidrosis Demand And Fulfillment Platform Will Support This Bullish Thesis
Catalysts About Botanix Pharmaceuticals Botanix Pharmaceuticals is a dermatology company focused on Sofdra, a prescription treatment for primary axillary hyperhidrosis. What are the underlying business or industry changes driving this perspective?Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Botanix...Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...We're Not Very Worried About Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...We Think Botanix Pharmaceuticals (ASX:BOT) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Botanix Pharmaceuticals...We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...The Botanix Pharmaceuticals (ASX:BOT) Share Price Has Gained 81% And Shareholders Are Hoping For More
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But one can do...We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Revenue & Expenses Breakdown
How Botanix Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 25 | 22 | -89 | 96 | 0 |
| 30 Sep 25 | 14 | -88 | 89 | 0 |
| 30 Jun 25 | 6 | -86 | 83 | 0 |
| 31 Mar 25 | 4 | -63 | 60 | 0 |
| 31 Dec 24 | 2 | -39 | 37 | 0 |
| 30 Sep 24 | 2 | -27 | 25 | 0 |
| 30 Jun 24 | 2 | -14 | 12 | 0 |
| 31 Mar 24 | 1 | -12 | 10 | 0 |
| 31 Dec 23 | 0 | -10 | 8 | 0 |
| 30 Sep 23 | 2 | -10 | 7 | 0 |
| 30 Jun 23 | 4 | -9 | 6 | 0 |
| 31 Mar 23 | 5 | -10 | 6 | 0 |
| 31 Dec 22 | 6 | -11 | 6 | 0 |
| 30 Sep 22 | 5 | -12 | 5 | 0 |
| 30 Jun 22 | 3 | -13 | 5 | 0 |
| 31 Mar 22 | 1 | -12 | 4 | 0 |
| 31 Dec 21 | 0 | -11 | 4 | 0 |
| 30 Sep 21 | 3 | -7 | 3 | 0 |
| 30 Jun 21 | 7 | -3 | 3 | 0 |
| 31 Mar 21 | 7 | -6 | 4 | 0 |
| 31 Dec 20 | 7 | -9 | 5 | 0 |
| 30 Sep 20 | 7 | -13 | 8 | 0 |
| 30 Jun 20 | 8 | -17 | 10 | 0 |
| 31 Mar 20 | 8 | -18 | 10 | 0 |
| 31 Dec 19 | 8 | -20 | 10 | 0 |
| 30 Sep 19 | 6 | -18 | 7 | 0 |
| 30 Jun 19 | 5 | -17 | 5 | 0 |
| 31 Mar 19 | 5 | -15 | 3 | 0 |
| 31 Dec 18 | 5 | -13 | 2 | 0 |
| 30 Sep 18 | 3 | -12 | 2 | 0 |
| 30 Jun 18 | 2 | -11 | 2 | 0 |
| 31 Mar 18 | 2 | -8 | 2 | 0 |
| 31 Dec 17 | 2 | -6 | 2 | 0 |
| 30 Sep 17 | 1 | -5 | 1 | 0 |
| 30 Jun 17 | 0 | -5 | 1 | 0 |
| 31 Dec 16 | 0 | -3 | 1 | 0 |
Quality Earnings: BOT is currently unprofitable.
Growing Profit Margin: BOT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BOT is unprofitable, and losses have increased over the past 5 years at a rate of 57.1% per year.
Accelerating Growth: Unable to compare BOT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BOT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-17.4%).
Return on Equity
High ROE: BOT has a negative Return on Equity (-164.28%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/31 16:19 |
| End of Day Share Price | 2026/07/31 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Botanix Pharmaceuticals Limited is covered by 2 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madeleine Williams | Canaccord Genuity |
| Joseph Pantginis | H.C. Wainwright & Co. |